Inito, a company focused on at-home healthcare solutions, has secured $2.9 million in new investment capital. This funding round will support the company's mission to make biological data more accessible and understandable for individuals.
The company's flagship product is an FDA-registered fertility monitor designed for at-home use. This device allows users to measure four key fertility hormones with a single test strip, providing results in approximately 10 minutes. Inito has gained significant traction, serving over 75,000 couples and achieving the #1 ranking for fertility trackers on Amazon. To date, users have conducted more than 5 million tests, contributing to a dataset of over 15 million data points that are enhancing the understanding of fertility.
This capital infusion is expected to accelerate Inito's growth initiatives and product development. The funds will be strategically deployed to expand the company's technological capabilities and broaden its offerings beyond fertility, aligning with its overarching goal of transforming lab-grade data into actionable everyday health insights. The investment underscores confidence in Inito's approach to closing critical gaps in at-home healthcare.
Headquartered in Houston, with a growing team in Bangalore and an R&D hub in Dubai, Inito employs over 100 engineers across hardware, software, and biosciences. The company is committed to leveraging innovation to provide comprehensive health insights from the inside out. Looking ahead, Inito plans to continue its expansion in the at-home healthcare market, aiming to empower more individuals with accessible and personalized health information.
